NASDAQ:SNNASienna Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sienna Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.14 0.00 (0.00 %) (As of 12/16/2019) Add Compare Share Today's Range$0.11Now: $0.14▼$0.1750-Day Range$0.14MA: $0.14▼$0.1452-Week Range$0.06Now: $0.14▼$3.80Volume13.32 million shsAverage Volume3.85 million shsMarket Capitalization$4.20 millionP/E RatioN/ADividend YieldN/ABeta2.67 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSienna Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Sienna Biopharmaceuticals has a potential upside of 2,109.1% from its current price of $0.14.Amount of Analyst CoverageSienna Biopharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSienna Biopharmaceuticals has received 366 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSienna Biopharmaceuticals has received 392 “underperform” votes. (Add your “underperform” vote.)Community SentimentSienna Biopharmaceuticals has received 51.72% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote “Outperform” if you believe SNNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSienna Biopharmaceuticals does not currently pay a dividend.Dividend GrowthSienna Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sienna Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 27.20% of the stock of Sienna Biopharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.36% of the stock of Sienna Biopharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sienna Biopharmaceuticals are expected to grow in the coming year, from ($3.10) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sienna Biopharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sienna Biopharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSienna Biopharmaceuticals has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNNA Previous Symbol CUSIPN/A CIK1656328 Webwww.siennabio.com Phone818-629-2256Debt Debt-to-Equity RatioN/A Current Ratio15.27 Quick Ratio15.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book0.11Profitability EPS (Most Recent Fiscal Year)($3.59) Net Income$-73,470,000.00 Net MarginsN/A Return on Equity-177.36% Return on Assets-52.22%Miscellaneous Employees39 Outstanding Shares30,910,000Market Cap$4.20 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:SNNA Rates by TradingView Receive SNNA News and Ratings via Email Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter. Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions How has Sienna Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Sienna Biopharmaceuticals' stock was trading at $0.1358 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SNNA shares have increased by 0.0% and is now trading at $0.1358. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sienna Biopharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sienna Biopharmaceuticals. How were Sienna Biopharmaceuticals' earnings last quarter? Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.10. View Sienna Biopharmaceuticals' earnings history. What price target have analysts set for SNNA? 1 brokers have issued 12 month target prices for Sienna Biopharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Sienna Biopharmaceuticals' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 2,109.1% from the stock's current price. View analysts' price targets for Sienna Biopharmaceuticals. Has Sienna Biopharmaceuticals been receiving favorable news coverage? Media headlines about SNNA stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sienna Biopharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Sienna Biopharmaceuticals. Who are some of Sienna Biopharmaceuticals' key competitors? Some companies that are related to Sienna Biopharmaceuticals include OTCMKTS:EMBI (EMBI), Mateon Therapeutics (MATN), MYOS (MYOS), China SXT Pharmaceuticals (SXTC), Cellectar Biosciences (CLRB), Novelion Therapeutics (NVLN), Novelion Therapeutics (NVLNF), Integrated BioPharma (INBP), Phio Pharmaceuticals (PHIO), BIOLINERX LTD/S (BLRX), Wellness Center USA (WCUI), Teligent (TLGT), GT Biopharma (GTBP), Sonoma Pharmaceuticals (SNOA) and Inspyr Therapeutics (NSPX). View all competitors. What other stocks do shareholders of Sienna Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sienna Biopharmaceuticals investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Selecta Biosciences (SELB), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Novavax (NVAX), Ring Energy (REI), Ring Energy (REI), Synergy Pharmaceuticals (SGYP) and ZEALAND PHARMA/S (ZEAL). Who are Sienna Biopharmaceuticals' key executives? Sienna Biopharmaceuticals' management team includes the following people: Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)Mr. Timothy K. Andrews Esq., Gen. Counsel & Corp. Sec. (Age 40)Mr. Alexander Azoy, CFO & Controller (Age 43)Mr. Majed Kheir, VP of Operations (Age 41)Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49) When did Sienna Biopharmaceuticals IPO? (SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO. What is Sienna Biopharmaceuticals' stock symbol? Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA." How do I buy shares of Sienna Biopharmaceuticals? Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sienna Biopharmaceuticals' stock price today? One share of SNNA stock can currently be purchased for approximately $0.14. How big of a company is Sienna Biopharmaceuticals? Sienna Biopharmaceuticals has a market capitalization of $4.20 million. The company earns $-73,470,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Sienna Biopharmaceuticals employs 39 workers across the globe. What is Sienna Biopharmaceuticals' official website? The official website for Sienna Biopharmaceuticals is www.siennabio.com. How can I contact Sienna Biopharmaceuticals? Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
